Infectious Diseases Drugs Markets

Content

• 1. Overview
  • 1.1 Statement Of Report
  • 1.2 Scope Of The Report
  • 1.3 Methodology
  • 1.4 Executive Summary
• 2. Clinical Syndromes And Therapy
  • 2.1 Head And Neck
    • 2.1.1 Sinusitis
    • 2.1.2 Pharyngotonsillitis
    • 2.1.3 Deep Neck Infections
    • 2.1.4 Otitis Media And Externa
    • 2.1.5 Acute Suppurative Thyroiditis
  • 2.2 Eye
    • 2.2.1 Conjunctivitis
    • 2.2.2 Keratitis
    • 2.2.3 Iritis
    • 2.2.4 Retinitis
    • 2.2.5 Endophthalmitis
  • 2.3 Skin And Lymph Nodes
    • 2.3.1 Complicated Skin And Skin Structure Infections (Csssi)
    • 2.3.2 Lymphadenitis
  • 2.4 Respiratory Tract
    • 2.4.1 Bronchitis
    • 2.4.2 Laryngitis
    • 2.4.3 Pneumonia
    • 2.4.4 Influenza
    • 2.4.5 Avian Bird Flu
    • 2.4.6 Swine Flu
    • 2.4.7 Respiratory Syncytial Virus
    • 2.4.8 Tuberculosis
  • 2.5 Heart And Blood Vessels
    • 2.5.1 Endocarditis
    • 2.5.2 Acute Pericarditis
    • 2.5.3 Myocarditis
    • 2.5.4 Vascular Infection
  • 2.6 Gastrointestinal Tract, Liver And Abdomen
    • 2.6.1 Acute Viral Hepatitis
    • 2.6.2 Chronic Hepatitis
    • 2.6.3 Biliary Tract Infection
    • 2.6.4 Pancreatitis
    • 2.6.5 Esophageal Infections
    • 2.6.6 Gastroenteritis
    • 2.6.7 Peritonitis
  • 2.7 Genitourinary Tract
    • 2.7.1 Urethritis
    • 2.7.2 Prostatitis
    • 2.7.3 Urinary Tract Infection
    • 2.7.4 Pelvic Inflammatory Disease
    • 2.7.5 Candiduria
    • 2.7.6 Human Papilloma Virus
  • 2.8 Nervous System
    • 2.8.1 Bacterial Meningitis
    • 2.8.2 Viral Encephalitis
    • 2.8.3 Reye S Syndrome
    • 2.8.4 Myelitis And Peripheral Neuropathy
  • 2.9 Musculoskeletal System
    • 2.9.1 Osteomyelitis
    • 2.9.2 Polyarthritis
    • 2.9.3 Bursitis
    • 2.9.4 Psoas Abscess
  • 2.10 Human Immunodeficiency Virus (Hiv) Infection
  • 2.11 Blood-Borne Infections
    • 2.11.1 Malaria
    • 2.11.2 West Nile Virus
• 3. Anti-Infective Agent Markets
  • 3.1 Fda Approvals Of New Anti-Infective Therapy
  • 3.2 Anti-Infective Agents In Current Pharmaceutical Developmental Programs
  • 3.3 Factors Determining Anti-Infective Drug Development
  • 3.4 Pharmaceutical R&d Expenditures
• 4. Description Of Anti-Infective Therapeutic Agents
  • 4.1 Anti-Bacterials
    • 4.1.1 Anti-Bacterial Therapeutic Agents In Current Formulation
      • 4.1.1.1 -Lactam Antibiotics
      • 4.1.1.2 Fluoroquinones
      • 4.1.1.3 Glycopeptides
      • 4.1.1.4 Macrolides
      • 4.1.1.5 Oxazolidinones
      • 4.1.1.6 Other Classes Of Anti-Bacterial Agents
    • 4.1.2 Older Classes Of Antibiotics
  • 4.2 Anti-Virals
    • 4.2.1 Overview
    • 4.2.2 Anti-Viral Therapy
    • 4.2.3 Anti-Viral Market Leaders
    • 4.2.4 Principles Of Anti-Viral Therapy
  • 4.3 Anti-Fungals
    • 4.3.1 Overview
    • 4.3.2 Major Classes Of Anti-Fungal Therapy
    • 4.3.3 Anti-Fungal Agent Resistance
    • 4.3.4 Anti-Fungal Agent Market Leaders
  • 4.4 Vaccines
    • 4.4.1 Overview
    • 4.4.2 Principles Of Vaccine Therapy
    • 4.4.3 Vaccine Market Leaders
• 5. Market For Anti-Infective Agents And Vaccines
  • 5.1 Molecular Diagnostics In Determining Demand
• 6. Decision-Making Activity In The Anti-Infective Market
  • 6.1 Net Present Value In Making Decisions To Develop And Market Antibiotics
• 7. Economics Of Anti-Microbial Drug Resistance: The Persistent Need For Anti-Bacterials
  • 7.1 Resistance And Antibiotic Usage
• 8. Global Market Analysis Of Anti-Infective Agents
  • 8.1 Market Size
  • 8.2 Market Share
  • 8.3 Market Drivers
• 9. Global Market For Anti-Bacterial Therapies
  • 9.1 Amoxicillin
  • 9.2 Nafcillin
  • 9.3 Ticarcillin
  • 9.4 Imipenem
  • 9.5 Ceftriaxone
  • 9.6 Cefotetan
  • 9.7 Dalbavancin
  • 9.8 Doripenem
• 10. Global Market For Anti-Fungal Therapies
  • 10.1 Amphotericin B
  • 10.2 Azoles
  • 10.3 Echinocandins
  • 10.4 Flucytosine
• 11. Global Market For Anti-Viral Therapies
  • 11.1 Antiretroviral Market
    • 11.1.1 The Viral Drug Resistance Crisis
    • 11.1.2 Emtricitabine
    • 11.1.3 Ccr5 Receptor Antagonists
    • 11.1.4 Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis)
  • 11.2 Hcv Infections
    • 11.2.1 Pegintron Alpha
    • 11.2.2 Ribavirin
    • 11.2.3 Boceprevir
  • 11.3 Acyclovir
  • 11.4 Adefovir
  • 11.5 Cidofovir
  • 11.6 Entecavir
  • 11.7 Fomivirsen
  • 11.8 Foscarnet
  • 11.9 Ganciclovir
• 12. Market, Demographic And Economic Trends
  • 12.1 Emerging Trends In Infectious Diseases Worldwide
  • 12.2 Global Burden Of Infectious Disease
  • 12.3 The Aids Model
  • 12.4 Dead-End Transmission Of Zoonotic And Vector-Borne Diseases
  • 12.5 Environmentally Persistent Organisms
  • 12.6 Old Microbes Cause New Disease
  • 12.7 Microbial Agents And Chronic Diseases
  • 12.8 Remerging And Resurging Infections
  • 12.9 Geographical Spread Of Infectious Disease
  • 12.10 Drug-Resistant Microbes
  • 12.11 Opportunistic Re-Emerging Infections
  • 12.12 Re-Emerging Zoonotic And Vector-Borne Diseases
  • 12.13 Influenza
  • 12.14 Deliberately Emerging Infections
  • 12.15 Meeting The Challenge Of Emerging Diseases
• 13. Political/Legal Trends
  • 13.1 Aatf And Legislation
  • 13.2 Bioterrorism And Biowarfare
• 14. Technological Trends
  • 14.1 Anti-Microbial Discovery In The Post-Genomic Era
    • 14.1.1 Anti-Bacterial Polypharmacology
    • 14.1.2 Topology Of Targets
    • 14.1.3 Designer Polypharmacology And Designing Hiv-Therapies
• 15. Socio-Cultural Trends
• 16. Competitive Landscape
  • 16.1 Introduction
  • 16.2 Strengths And Weaknesses In Anti-Microbial Drug Discovery Commercial
  • 16.3 Strengths And Weaknesses In Anti-Microbial Drug Discovery Academic
  • 16.4 Regulatory Hurdles
  • 16.5 Business Hurdles
  • 16.6 Strategic Alliances, Licensing Activity, And Mergers & Acquisitions In The Anti-Infectives Landscape
• 17. Sales Performance Amongst The Leading Players: Detailed Analysis Of Leading Anti-Infective Players
  • 17.1 Glaxosmithkline
    • 17.1.1 Overview
    • 17.1.2 Sales Focus By Drug Class
    • 17.1.3 Marketed Product Portfolio
    • 17.1.4 R&d Pipeline Analysis
    • 17.1.5 Strategic And Growth Analysis
  • 17.2 Merck
    • 17.2.1 Overview
    • 17.2.2 Sales Focus By Drug Class
    • 17.2.3 Marketed Product Portfolio
    • 17.2.4 R&d Pipeline Analysis
    • 17.2.5 Strategic And Growth Analysis
  • 17.3 Pfizer
    • 17.3.1 Overview
    • 17.3.2 Sales Focus By Drug Class
    • 17.3.3 Marketed Product Portfolio
    • 17.3.4 R&d Pipeline Analysis
    • 17.3.5 Strategic And Growth Analysis
  • 17.4 Novartis
    • 17.4.1 Overview
    • 17.4.2 Sales Focus By Drug Class
    • 17.4.3 Marketed Product Portfolio
    • 17.4.4 R&d Pipeline Analysis
    • 17.4.5 Strategic And Growth Analysis
  • 17.5 Gilead Sciences
    • 17.5.1 Overview
    • 17.5.2 Sales Focus By Drug Class
    • 17.5.3 Marketed Product Portfolio
    • 17.5.4 R&d Pipeline Analysis
    • 17.5.5 Strategic And Growth Analysis
  • 17.6 Abbott
    • 17.6.1 Overview
    • 17.6.2 Sales Focus By Drug Class
    • 17.6.3 Marketed Product Portfolio
    • 17.6.4 R&d Pipeline Analysis
    • 17.6.5 Strategic And Growth Analysis
  • 17.7 Wyeth
    • 17.7.1 Overview
    • 17.7.2 Sales Focus By Drug Class
    • 17.7.3 Marketed Product Portfolio
    • 17.7.4 R&d Pipeline Analysis
    • 17.7.5 Strategic And Growth Analysis
  • 17.8 Sanofi-Aventis
    • 17.8.1 Overview
    • 17.8.2 Sales Focus By Drug Class
    • 17.8.3 Marketed Product Portfolio
    • 17.8.4 R&d Pipeline Analysis
    • 17.8.5 Strategic And Growth Analysis
  • 17.9 Bristol-Myers Squibb
    • 17.9.1 Overview
    • 17.9.2 Sales Focus By Drug Class
    • 17.9.3 Marketed Product Portfolio
    • 17.9.4 R&d Pipeline Analysis
    • 17.9.5 Strategic And Growth Analysis
  • 17.10 Johnson & Johnson
    • 17.10.1 Overview
    • 17.10.2 Sales Focus By Drug Class
    • 17.10.3 Marketed Product Portfolio
    • 17.10.4 R&d Pipeline Analysis
    • 17.10.5 Strategic And Growth Analysis
  • 17.11 Roche Pharma Ag
    • 17.11.1 Overview
    • 17.11.2 Sales Focus By Drug Class
    • 17.11.3 Marketed Product Portfolio
    • 17.11.4 R&d Pipeline Analysis
    • 17.11.5 Strategic And Growth Analysis
• 18. Company Profiles
  • 18.1 Abraxis Bioscience, Inc
  • 18.2 Acambis
  • 18.3 Achillion Pharmaceuticals, Inc
  • 18.4 Adlyfe, Inc
  • 18.5 Advanced Life Sciences Holdings, Inc
  • 18.6 Affinium Pharmaceuticals
  • 18.7 Akonni Biosystems
  • 18.8 Alnylam Pharmaceuticals
  • 18.9 App Pharmaceuticals
  • 18.10 Aquapharm Biodiscovery
  • 18.11 Arbor Vita Corporation
  • 18.12 Arpida Ltd
  • 18.13 Avexa Ltd
  • 18.14 Basilea Pharmaceutica Ag
  • 18.15 Baxter International, Inc
  • 18.16 Biophage Pharma, Inc
  • 18.17 Cel-Sci Corporation
  • 18.18 Cerexa, Inc. (Subsidiary Of Forest Laboratories)
  • 18.19 Combimatrix Corporation
  • 18.20 Cubist Pharmaceuticals, Inc
  • 18.21 Daiichi Sankyo Co., Ltd
  • 18.22 Hospira, Inc
  • 18.23 Incyte Corporation
  • 18.24 Idenix Pharmaceuticals, Inc
  • 18.25 Medivir Ab
  • 18.26 Meiji Holdings Co., Ltd
  • 18.27 Merlion Pharmaceuticals
  • 18.28 Mutabilis
  • 18.29 Nanobio Corporation
  • 18.30 Nanosphere, Inc
  • 18.31 Nanoviricides, Inc
  • 18.32 Novabay Pharmaceuticals, Inc
  • 18.33 Obetech, Llc
  • 18.34 Optimer Pharmaceuticals, Inc
  • 18.35 Panacos Pharmaceuticals, Inc
  • 18.36 Paratek Pharmaceuticals, Inc
  • 18.37 Pharmasset, Inc
  • 18.38 Pico Pharmaceuticals, Inc
  • 18.39 Polymedix, Inc
  • 18.40 Powdermed Ltd. (Subsidiary Of Pfizer)
  • 18.41 Presidio Pharmaceuticals, Inc
  • 18.42 Progenics Pharmaceuticals, Inc
  • 18.43 Protez Pharmaceuticals (A Novartis Subsidiary)
  • 18.44 Ribomed Biotechnologies, Inc
  • 18.45 Rib-X Pharmaceuticals, Inc
  • 18.46 Targanta Therapeutics Corporation, Inc
  • 18.47 Theravance, Inc
  • 18.48 Trius Therapeutics
  • 18.49 Vertex Pharmaceuticals, Inc
  • 18.50 X-Gen Pharmaceuticals, Inc
  • Appendix 1: Fda Compliance Policies Regarding Approved New Drug And Antibiotic Drug Products
  • Appendix 2: Anti-Hcv Drugs In Development
  • Appendix 3: The Market For Anti-Infectives In Animal Health
  • Appendix 4: Diagnostics For Infectious Agents
• Index Of Figures
  • Figure 1.1: Leading Causes Of Death In The U.S., 1958-2005
  • Figure 1.2: Global Distribution Of Anti-Infective Agent Sales By Geography
  • Figure 2.1: Incidence Rates Of Invasive Methicillin-Resistant S. Aureus (Mrsa) Infections By Age
  • Figure 2.2: U.S. Child Death Rate From Preventable Diseases, 2007
  • Figure 2.3: Infection Rate Of Serotype 19a By Age Group In The U.S., 1998-2006
  • Figure 2.4: U.S. Hospitalizations For Types Of Respiratory Diseases In Children Under 15 Years Of Age, 2005
  • Figure 2.5: Economic Burden Of Select Lung Diseases In The U.S., 2007
  • Figure 2.6: Infection Rate Of Invasive Pneumococcal Disease In The U.S., 1998-2006
  • Figure 2.7: Status Of H5n1 Avian Influenza, 2009
  • Figure 2.8: Number Of Reported And Confirmed Cases Of Influenza H1n1 Strain Worldwide, 2009
  • Figure 2.9: Distribution Of H1n1 Flu In The U.S., August 2009
  • Figure 2.10: Novel H1n1 Confirmed And Probable Case Rate In The U.S., By Age Group
  • Figure 2.11: Number Of Tuberculosis (Tb) Cases Among U.S. - And Foreign-Born Persons, By Year Reported In The U.S., 1993-2008
  • Figure 2.12: Rate Of Tuberculosis (Tb) Cases Among U.S. - And Foreign-Born Persons, By Year Reported In The U.S., 1993-2008
  • Figure 2.13: Rate Of Tuberculosis (Tb) Cases By State/Area In The U.S., 2008
  • Figure 2.14: U.S.-Born Tb Cases By Ethnicity, 2008
  • Figure 2.15: Rate Of New Hepatitis A, Hepatitis B And Hepatitis C Infections In The U.S., 1982-2006
  • Figure 2.16: Countries Reporting Outbreaks Of Cholera, 2006-2008
  • Figure 2.17: U.S. Rates Of Sexually-Transmitted Diseases, 1940-2007
  • Figure 2.18: Rate Of New Cases And Deaths Of Cervical Cancer By Age Group Worldwide, 2008
  • Figure 2.19: Global Trend Of Hiv Infection, 1991-2007
  • Figure 2.20: Worldwide Percentage Of Adults Living With Hiv, 1990-2006
  • Figure 2.21: Worldwide Rate Of New Hiv Cases, 1990-2007
  • Figure 2.22: Percentage Of Adult Population In African Countries With Hiv, 2007
  • Figure 2.23: Ethnic Distribution Of Aids Patients In The U.S., 2007
  • Figure 2.24: Ten Best Selling Aids Drugs In The U.S., 2008
  • Figure 2.25: U.S. Rates For New Hiv Cases, 2008
  • Figure 2.26: Global Malaria-Endemic Areas In The Eastern Hemisphere
  • Figure 2.27: Anti-Malarial Vaccine Pipeline, 2009
  • Figure 2.28: Global Anti-Malarial Drug Pipeline, 2008
  • Figure 2.29: West Nile Virus Activity In The U.S., 2009
  • Figure 3.1: Anti-Infective Drug Market Projections, 2006-2013
  • Figure 3.2: Leading Companies In Anti-Infectives Market Share, 2008
  • Figure 3.3: Number Of New Anti-Bacterial Agents Approved By The Fda In The U.S., 1983-2008
  • Figure 3.4: Total Spending On Healthcare In The U.S., 1960-2008
  • Figure 3.5: Percentage Breakdown Of U.S. Healthcare Spending, 2008
  • Figure 3.6: International Per Capita Healthcare Spending By Country, 2006
  • Figure 3.7: Generic Drug Applications And Approvals In The U.S., 1995-2006
  • Figure 3.8: Savings Generated By Generic Use In The U.S., By Therapeutic Category, 1999-2008
  • Figure 3.9: Anti-Bacterial And Anti-Hiv New Molecular Entities (Nmes) Approved By The Fda, 1993-2007
  • Figure 3.10: Cost For New Drugs By Primary Indication, 2007
  • Figure 4.1: Market Share By Leading Anti-Bacterial Drug Class
  • Figure 4.2: Anti-Virals In The Marketplace, 2004
  • Figure 4.3: Anti-Viral Market By Indication, Excluding Hiv And Hcv
  • Figure 4.4: Anti-Viral Therapeutics Market, By Drug Class
  • Figure 4.5: Global Distribution Of The Lack Of Childhood Vaccination
  • Figure 4.6: Gavi Alliance Members
  • Figure 4.7: Global Vaccines Market, 2008
  • Figure 4.8: Glaxosmithkline S Vaccine Pipeline, 2008
  • Figure 4.9: The Vaccine Market By Geographical Area, 2008
  • Figure 5.1: Global Market For Molecular Diagnostics, 2002-2013
  • Figure 6.1: Number Of Non-Elderly Americans Without Health Insurance Coverage, 1994-2007
  • Figure 6.2: Percentage Of Non-Elderly Americans Without Health Insurance Coverage, 1994-2007
  • Figure 7.1: Global Multidrug Susceptibility In P. Aeruginosa
  • Figure 7.2: Global Frequency Of Vancomycin-Resistant Enterococci, 2006
  • Figure 7.3: Mrsa Trends According To Patient Location, 1998-2005
  • Figure 9.1: Projected Growth In Market For Injectable Anti-Bacterials, 2008 And 2013
  • Figure 9.2: Real And Projected Market Shares For Major Anti-Bacterial Classes, 2008 And 2013
  • Figure 9.3: Frequency Of S. Aureus In Skin And Soft Tissue Infections
  • Figure 11.1: Current And Projected Market Size For Injectable Antiretrovirals By Class, 2008 And 2013
  • Figure 11.2: Market Share For Injectable Antiretrovirals By Drug Class, 2008
  • Figure 11.3: The Changing Face Of The Hcv Market: Growth And Projections By Drug Class, 2008 And 2013
  • Figure A3.1: Growth In Global Sales Of Antibiotic Products In Animal Health, 2005-2012
  • Figure A4.1: Find Pipeline For Tb Diagnostics
• Index Of Tables
  • Table 1.1: Top Ten Causes Of Death Worldwide
  • Table 1.2: Leading Pharmaceutical Companies In The Anti-Infective Market Total Global Sales, 2008
  • Table 2.1: Annual Rates Of Global Infectious Diseases
  • Table 2.2: Drugs In Development For Chronic Hepatitis B, 2009
  • Table 2.3: Global Hiv Statistics, 2007
  • Table 3.1: Top Selling Anti-Infective Agents, 2008
  • Table 3.2: Sales For Leading Companies Infectious Diseases Segments, 2008
  • Table 3.3: Current Drug Development Times And Rates, By Therapeutic Indication
  • Table 3.4: Emerging Therapeutic Approaches
  • Table 3.5: New Drug Approvals In All Categories From Fda, 2000-2008
  • Table 3.6: Top Ten Global Pharmaceutical Markets, 2008
  • Table 3.7: Bric Countries, Percentage Of Gdp Spent On Healthcare, 2008
  • Table 3.8: Percentage Of Gdp Healthcare Spending By Country, 2008
  • Table 3.9: Top 20 Generic Drugs By Prescriptions, 2008
  • Table 3.10: Anti-Bacterial Agents Undergoing Clinical Development
  • Table 3.11 Leading Tuberculosis R&d Candidates
  • Table 3.12: Pipeline For Repositioned Drugs
  • Table 4.1: Potential Anti-Bacterial Protein Drug Targets
  • Table 4.2: In Vitro Susceptibility Of Staphylococci To New Agents In Development
  • Table 4.3: Anti-Staphylococcal Vaccines And Immunoglobulins In The Late Stage Pipeline, 2009
  • Table 4.4: Bacterial Targets Of Antibiotics And Resistance Mechanisms
  • Table 4.5: Guideline Summary For Antibiotic Selection For Skin And Soft Tissue Infections
  • Table 4.6: Selected Anti-Viral Drugs
  • Table 4.7: Anti-Reterovirals In Development, 2008
  • Table 4.8: New Types Of Hiv Drugs
  • Table 4.9: Recommended Daily Dosage Of Seasonal Influenza Anti-Viral Medications For Treatment And Chemoprophylaxis In The U.S., 2008-2009
  • Table 4.10: Percentage Drug Resistance For Common Influenza Virus Strains, 2009
  • Table 4.11: Selected Hcv Drugs In Development, 2009
  • Table 4.12: Therapeutic Agents In Development For Treating Hepatitis B, 2008
  • Table 4.13: Anti-Fungal Compounds In Late Stage Development
  • Table 4.14: New Vaccines Licensed, 2005-2008
  • Table 4.15: Global Top Selling Blockbuster Vaccines, 2008
  • Table 4.16: Selected Anti-Infective Monoclonal Antibodies In Clinical Development, 2009
  • Table 5.1: Fda-Approved Commercial Kits For The Detection Of Infectious Agents
  • Table 5.2: Examples Of Personalized Medicine In Treatment Of Infectious Disease
  • Table 6.1: Competitive Landscape For Anti-Viral Drugs In Development, 2009
  • Table 6.2: Competitive Landscape For Anti-Biotic Drugs In Development, 2009
  • Table 8.1 Anti-Hiv Therapeutics Approved By The Fda
  • Table 9.1: Major Classes Of Antibiotics
  • Table 10.1: Major Classes Of Anti-Fungals
  • Table 11.1: Ccr-5 Receptor Agonists In Development, 2009
  • Table 12.1: Major Pathogens Identified In The Last 30 Years
  • Table 12.2: Emerging And Re-Emerging Infectious Diseases And Their Geographical Location
  • Table 16.1: Pharmaceutical Companies Ranked By Total R&d Expenditures, 2008
  • Table 16.2: International Regulatory Measures Indicated By The International Forum Of Anti-Bacterial Resistance
  • Table A2.1: Anti-Hcv Pipeline, 2009
  • Table A3.1: U.S. Volume Of Animal Health Antibiotics Used, 2000-2006
  • Table A3.2: European Sales Of Animal Health Antibiotics, 2005-2012
  • Table A3.3: Use Of Antibiotics As Growth Promotants
  • Table A4.1: The Market Structure For Infectious Disease Diagnostics
  • Table A4.2: Rapid Strep Tests On The Market
  • Table A4.3: Rapid Tests For Chlamydia
  • Table A4.4: Rapid Tests For Gonorrhea
  • Table A4.5: The Burden Of Influenza
  • Table A4.6: Global Market Potential For Tb Diagnostic Testing
  • Table A4.7: Global Market For Hbv Diagnostic Testing
  • Table A4.8: U.S. Market For Hbv Diagnostic Testing
  • Table A4.9: Serological Diagnosis Of Hepatitis B Virus Infections
  • Table A4.10: Lower Detection Limits Of Hbv Dna Assays
  • Table A4.11: Summary Of Hepatitis B Test Technology
  • Table A4.12: Global Market For Hcv Diagnostic Testing
  • Table A4.13: Efficiency Of Available Hcv Screening Tests
  • Table A4.14: Recommendations For Diagnostic Testing For Hepatitis C